Pharmamar confirms Positive Results For Aplidin To Combat Coronavirus

pharmaMarPharmaMar's shares in fact shot up 78% in the early part of Friday's session

PharmaMar’s shares were trading slightly lower, down 0.20%, at midday today. However that is following a rebound of 33% on Friday, making it the best performing stock on the Spanish stock market. This was after the company announced positive results from studies on Aplidin to combat the coronavirus. As a result, it will ask for tests to be carried out on infected patients. Shares in the Spanish pharmaceutical, which were “blocked” for almost three hours in pre-opening Friday, closed at 3.35 euros each, up from 2.52 euros at Thursday’s close.

PharmaMar’s shares in fact shot up 78% in the early part of Friday’s session, when they were trading at 4.48 euros each. Afterwards they moderated their advance.

The pharmaceutical company will contact the regulatory authorities to analyse the possibilities of carrying out studies on patients infected with Covid-19. This is in the wake of trial results confirming the hypothesis that the therapeutic target of Aplidin (plitidepsin), the protein EF1A which is present in the human body, is key to the multiplication and spread of the virus.

About the Author

The Corner
The Corner has a team of on-the-ground reporters in capital cities ranging from New York to Beijing. Their stories are edited by the teams at the Spanish magazine Consejeros (for members of companies’ boards of directors) and at the stock market news site Consenso Del Mercado (market consensus). They have worked in economics and communication for over 25 years.